Which of the following statements is/are TRUE ABOUT Trulicity? [Select ALL THAT APPLY].
a. The active ingredient is Dulaglutide.
b. It is indicated for the treatment of migraine.
c. It is a glucagon-like peptide-1 (GLP-1) receptor agonist.
d. Initiate at 0.75 mg subcutaneously once weekly.
e. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
The active ingredient found in Trulicity is Dulaglutide. It is available as an injection (0.75mg/0.5ml, 1.5mg/0.5ml) administered subcutaneously in the abdomen, thigh, or upper arm.
It is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated:
1. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2. to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.
The drug should be administered once weekly. The drug should be initiated at 0.75 mg subcutaneously once weekly. Dose can be increased to 1.5 mg once weekly for additional glycemic control.
If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose.
It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
Nausea, diarrhea, vomiting, abdominal pain, and decreased appetite are commonly reported side effects of the drug.
Try our Naplex QBank. www.pharmacyexam.com